Skip to main content
. Author manuscript; available in PMC: 2018 Jun 15.
Published in final edited form as: Oncogene. 2017 Jan 23;36(24):3441–3449. doi: 10.1038/onc.2016.494

Figure 4.

Figure 4

PU-H71 significantly reduces the viability of CLL cells but has minimal effects on PBMC or resting B cells. (a) Time course of the viability of PU-H71-treated CLL cells (N =44). Percentage of PI-positive cells were analyzed by flow cytometry. (b) Dose dependence of the viability of PU-H71-treated CLL cells (N =10). Cells were treated for 72 h. (c) Effect of PU-H71 on PBMCs (N =8). Cells were treated with the drug at indicated concentrations for 72 h. (d) Effect of PU-H71 on resting B cells (N =8). Cells were treated with the drug at indicated concentrations for 72 h. Bars represent means ± s.e.m. *P<0.05; **P<0.01.